European Commission

#AI #Cell and gene therapy #Charles River #Drug discovery #European Commission #European Union #FDA #Immune cells #Korea #Obesity #Personalised medicine #Rare disease #Regulatory

DDW Highlights: 23 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated… Read More

#Podcasts

#AI #Cell and gene therapy #Charles River #Drug discovery #European Commission #European Union #FDA #Immune cells #Korea #Obesity #Personalised medicine #Rare disease #Regulatory

This week in Drug Discovery (15 – 19 December) 

News round-up for 15 – 19 December by Bruno Quinney, Content Team at DDW.  This week in DDW, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated antibodies have been tolerated by human immune cells.  The top stories:    Scientists discover hidden molecular switch that… Read More

#News

European Commission
#EU #European Commission #European Medicines Agency #Personalised medicine #Regulatory

New agreement to reshape EU pharmaceutical legislation

A landmark political agreement has been reached by the European Commission, the European Parliament and the Council of the European Union on a comprehensive reform of the EU pharmaceutical legislation. The agreement represents the most significant overhaul of the regulatory framework in over two decades and is described as a… Read More

#News #Regulatory #Trending News

Blood tests in laboratory
#Crohn's disease #European Commission #Ulcerative colitis (UC)

World’s first liquid infliximab formulation approved for market 

The European Commission (EC) has granted marketing authorisation for the world’s first liquid formulation of infliximab.  Remsima is an intravenous liquid formulation used to treat autoimmune diseases including Crohn’s disease and ulcerative colitis. Remsima was first approved in September 2013 and launched in major EU countries in 2015 as a… Read More

#News

Close up of vaccine syringe
#Asthma #Cold Urticaria #European Commission

Omlyclo set for line extension after EC approval 

The European Commission (EC) has granted a line extension in the European Union for Omlyclo (omalizumab), Europe’s first and only omalizumab biosimilar.  The EC approved Omlyclo 300mg/2ml prefilled syringe, following approval for 75mg/0.5ml and 150mg/1ml solutions in May 2024.  Omlyclo is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with… Read More

#News #Regulatory

European biotech
#Biologics / Biotechnology #Biotech #Europe #European Commission #European Union

Is the European Biotech Act a one-shot solution for the biotech sector?

For European Biotech Week, Diana Turner and Dr Claire Skentelbery, Director General, EuropaBio, examine the potential impact of the European Biotech Act. The European Biotech Act was first introduced by Ursula von der Leyen in 2024 in her paper ‘Europe’s Choice: Political Guidelines For The Next European Commission 2024−2029’. She… Read More

#Exclusive Content #Trends & Analysis

Drugs targeting amyloid Plaque
#Alzheimer's #Eli Lilly #European Commission #Neurodegenerative disorders #Neuroscience

European Commission extends EU use of Lilly’s donanemab

The European Commission (EC) has granted marketing authorisation for Lilly’s Kisunla (donanemab) in early symptomatic Alzheimer's disease (AD).  It is approved in adults with mild cognitive impairment as well as those with mild dementia stages of AD with confirmed amyloid pathology who are apolipoprotein E (ApoE4) heterozygotes or non-carriers.  "Kisunla… Read More

#News #Regulatory

#Brain cancer #European Commission #Oncology #Servier Pharmaceuticals

Servier’s targeted brain tumour therapy approved in EU

The European Commission has approved pharmaceutical company Servier’s Voranigo therapy for patients with a specific type of brain tumour.   Voranigo has now been approved for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) R132 or isocitrate dehydrogenase-2 (IDH2) R172 mutation in adult and… Read More

#News #Regulatory

European Commission
#Autolus #CAR-T #Cell therapy #European Commission #Leukaemia #Oncology

Autolus Therapeutics’ CAR-T therapy gets EU green light

The European Commission (EC) has granted marketing authorisation for Aucatzyl (obecabtagene autoleucel or ‘obe-cel’) for the treatment of adult patients, 26+, with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL).  The EC approval was based on the results of the FELIX study, an open-label, multi centre, single arm… Read More

#News #Regulatory

Cancer cells
#Breast cancer #European Commission #Oncology #Roche

EC approves Roche’s Itovebi for breast cancer subtype

The European Commission has approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. It is approved following recurrence on or within 12 months of completing… Read More

#News #Regulatory

Map of Europe
#Clinical trials #EFPIA #Europe #European Commission #European Union

Group warns European clinical research is at risk

A broad group of 14 organisations, working in the European clinical trial sector, have issued a warning that without urgent implementation of the Life Science Strategy (LSS), Europe’s clinical trial eco-system is in a perilous situation.  The stakeholders—including academic and industry sponsors, investigators, and professional societies—formed earlier this year to… Read More

#Business & Investment #News

European Commission President Ursula von der Leyen
#Biotech #Biotech hubs #Europe #European Commission #European Union #Market reporting

Can Europe take the lead on biotech?

With uncertainty across the global financial markets and research community, is it Europe’s time to take the lead on biotech? Diana Turner reports.  While biotech has so far been dominated by the US, since the inauguration of Donald Trump in January 2025, there has been considerable uncertainty, with significant cuts… Read More

#Exclusive Content #Market Reports #Trends & Analysis

#Drug discovery #Europe #European Commission #European Union

New DDW Highlights podcast: 14 July 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week our news highlights focus on the drug discovery in the European Union, including… Read More

#News

#Drug discovery #Europe #European Commission #European Union

This week in drug discovery (7-11 July) 

News round-up for 7-11 July by DDW Senior Digital Content Editor Diana Turner. This week our news highlights focus on the drug discovery in the European Union, including some new regulatory approvals from the European Commission, advancements from Netherlands-based argenx, a new PhD programme in Estonia, and Switzerland’s… Read More

#News

Double stranded DNA molecule with mutation in a gene
#Cystic fibrosis #European Commission #Gene mutation #Vertex

EC approves Vertex’s CFTR modulator for cystic fibrosis

The European Commission (EC) has granted approval for Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (CF) ages six years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.  “Thousands of people with CF across… Read More

#News

Bladder
#AstraZeneca #Bladder cancer #European Commission #Monoclonal antibodies #Oncology

EU-approved bladder cancer therapy reduces death risk by 25%

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment.  According to the decision, this treatment should be followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy (surgery… Read More

#Cancer Research #News #Regulatory